| Revenue growth | Organic revenue up 13.7% FY26, beating the 13% guidance upper end. |
|---|---|
| Margins | EBITDA margin expanded 140bps to 25.9%, targeting 27-28% by FY28. |
| Demand visibility | Strong trends in specialized testing (Genomics) and wellness segments. |
| Management confidence | Confident, shifting from aggressive lab rollouts to throughput-led productivity. |
Growth
Organic revenue grew 13.7% in FY26, exceeding the guided 12-13%. Growth is healthy, split between 9.3% volume and 5% realization.
Outlook
Guided 14-15% revenue CAGR over three years with EBITDA margins reaching 27-28% by FY28.
Risks
Expansion of 'mini-hubs' increases capex risk; reliance on high-end genomics might face specialized competition.
Earnings Call filed with BSE, NSE: METROPOLIS. Summary written with AI assistance from the document.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹541.45
- Market cap
- ₹11,233 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 55.7×Sector 53.1×
- Promoter holding
- 48.86%-0.01% QoQ
- FII holding
- 11.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Employee Stock Options
Metropolis Healthcare allotted 66,312 equity shares to employees under its RSU Plan, 2020. This exercise follows the vesting of RSUs previously granted to staff.
Metropolis Healthcare Merger & Restructuring Worth ₹1.26 Cr
Metropolis Healthcare's subsidiary MQSPL will issue shares to Medsource and Dr. Puneet Kumar Nigam for ₹1.26 Crore, diluting MHL's stake to 54.90% through this strategic restructuring.
- Value
- ₹1.26 Cr
Metropolis Healthcare Capital Structure Change
Franklin Templeton Mutual Fund acquired 7,42,409 Metropolis Healthcare shares via open market, raising its stake to 5.10%. No transaction value was disclosed in the filing.
Metropolis Healthcare Merger & Restructuring Worth ₹1.25 Cr
Metropolis Healthcare transferred its External Quality Assessment Services Division to subsidiary MQSPL for ₹1.25 Crore. The transfer was executed via a slump sale.
- Value
- ₹1.25 Cr
Metropolis Healthcare Merger & Restructuring Worth ₹0.01 Cr
Metropolis Healthcare's subsidiary, MQSPL, will issue 10,000 Optionally Convertible Redeemable Preference Shares (OCRPS) to Dr. Puneet Kumar Nigam. Post-conversion, MQSPL will remain a subsidiary.
- Value
- ₹0.01 Cr
Metropolis Healthcare Annual General Meeting
Metropolis Healthcare held its 26th Annual General Meeting on August 18, 2026. Shareholders reviewed financial statements and confirmed previous interim dividend payments.